PubRank

Tomasz Huzarski

Author PubWeight™ 101.17‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet 2010 4.96
2 Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst 2010 4.54
3 Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol 2009 4.19
4 RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet 2007 3.63
5 Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Hum Mol Genet 2011 2.72
6 A range of cancers is associated with the rs6983267 marker on chromosome 8. Cancer Res 2008 2.43
7 Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet 2013 2.39
8 A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 2004 1.96
9 Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. J Clin Oncol 2011 1.94
10 Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. Cancer Res 2010 1.90
11 Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer. Breast Cancer Res 2012 1.81
12 Oophorectomy after menopause and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2012 1.78
13 A novel founder CHEK2 mutation is associated with increased prostate cancer risk. Cancer Res 2004 1.60
14 Early radiation exposures and BRCA1-associated breast cancer in young women from Poland. Breast Cancer Res Treat 2008 1.59
15 Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. Hum Mol Genet 2011 1.51
16 Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2010 1.41
17 A deletion in CHEK2 of 5,395 bp predisposes to breast cancer in Poland. Breast Cancer Res Treat 2006 1.34
18 Hereditary ovarian cancer in Poland. Int J Cancer 2003 1.30
19 Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2012 1.17
20 Should all BRCA1 mutation carriers with stage I breast cancer receive chemotherapy? Breast Cancer Res Treat 2013 1.16
21 Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res 2012 1.10
22 A high frequency of BRCA2 gene mutations in Polish families with ovarian and stomach cancer. Eur J Hum Genet 2003 1.08
23 CDKN2A common variants and their association with melanoma risk: a population-based study. Cancer Res 2005 1.08
24 The risk of breast cancer in women with a BRCA1 mutation from North America and Poland. Int J Cancer 2011 1.06
25 Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland. Breast Cancer Res Treat 2006 1.05
26 Constitutional CHEK2 mutations are associated with a decreased risk of lung and laryngeal cancers. Carcinogenesis 2008 1.04
27 The 3020insC Allele of NOD2 Predisposes to Cancers of Multiple Organs. Hered Cancer Clin Pract 2005 1.04
28 MC1R common variants, CDKN2A and their association with melanoma and breast cancer risk. Int J Cancer 2006 1.04
29 The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers. Cancer Epidemiol Biomarkers Prev 2007 1.03
30 Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations? Eur J Hum Genet 2006 1.02
31 BRCA1 mutations and prostate cancer in Poland. Eur J Cancer Prev 2008 1.01
32 PARP-1 expression in breast cancer including BRCA1-associated, triple negative and basal-like tumors: possible implications for PARP-1 inhibitor therapy. Breast Cancer Res Treat 2011 0.99
33 CDKN2A common variant and multi-organ cancer risk--a population-based study. Int J Cancer 2006 0.99
34 Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum Mutat 2012 0.98
35 Methylenetetrahydrofolate reductase polymorphisms modify BRCA1-associated breast and ovarian cancer risks. Breast Cancer Res Treat 2006 0.98
36 The G84E mutation in the HOXB13 gene is associated with an increased risk of prostate cancer in Poland. Prostate 2013 0.97
37 BRCA1-associated breast and ovarian cancer risks in Poland: no association with commonly studied polymorphisms. Breast Cancer Res Treat 2009 0.95
38 Genetic contribution to all cancers: the first demonstration using the model of breast cancers from Poland stratified by age at diagnosis and tumour pathology. Breast Cancer Res Treat 2008 0.95
39 Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Res Treat 2014 0.93
40 Increased rates of chromosome breakage in BRCA1 carriers are normalized by oral selenium supplementation. Cancer Epidemiol Biomarkers Prev 2005 0.91
41 Elevated level of 8-oxo-7,8-dihydro-2'-deoxyguanosine in leukocytes of BRCA1 mutation carriers compared to healthy controls. Int J Cancer 2009 0.91
42 Different CHEK2 germline mutations are associated with distinct immunophenotypic molecular subtypes of breast cancer. Breast Cancer Res Treat 2011 0.90
43 Distal intramural spread of rectal cancer after preoperative radiotherapy: the results of a multicenter randomized clinical study. Int J Radiat Oncol Biol Phys 2006 0.90
44 Selenium supplementation reduced oxidative DNA damage in adnexectomized BRCA1 mutations carriers. Cancer Epidemiol Biomarkers Prev 2009 0.89
45 The VEGF_936_C>T 3'UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women. Cancer Lett 2008 0.89
46 A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2012 0.89
47 Prevalence of the NOD2 3020insC mutation in aggregations of breast and lung cancer. Breast Cancer Res Treat 2006 0.89
48 BRCA1 mutations and colorectal cancer in Poland. Fam Cancer 2010 0.89
49 A common nonsense mutation of the BLM gene and prostate cancer risk and survival. Gene 2013 0.89
50 A six-nucleotide deletion in the CASP8 promoter is not associated with a susceptibility to breast and prostate cancers in the Polish population. Breast Cancer Res Treat 2007 0.89
51 BRCA1-related gene signature in breast cancer: the role of ER status and molecular type. Front Biosci (Elite Ed) 2011 0.88
52 Haplotype structure in Ashkenazi Jewish BRCA1 and BRCA2 mutation carriers. Hum Genet 2011 0.87
53 DNA variation in MSR1, RNASEL and E-cadherin genes and prostate cancer in Poland. Urol Int 2007 0.87
54 Synergistic interaction of variants in CHEK2 and BRCA2 on breast cancer risk. Breast Cancer Res Treat 2008 0.87
55 CDKN2A-positive breast cancers in young women from Poland. Breast Cancer Res Treat 2006 0.87
56 CHEK2 mutations and HNPCC-related colorectal cancer. Int J Cancer 2010 0.87
57 Immunophenotypic predictive profiling of BRCA1-associated breast cancer. Virchows Arch 2010 0.86
58 Large BRCA1 and BRCA2 genomic rearrangements in Polish high-risk breast and ovarian cancer families. Mol Biol Rep 2013 0.86
59 Clinical characteristics of laryngeal cancer in BRCA-1 mutation carriers. Anticancer Res 2009 0.85
60 The 3' untranslated region C > T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation. Breast Cancer Res Treat 2006 0.85
61 Variant alleles of the CYP1B1 gene are associated with colorectal cancer susceptibility. BMC Cancer 2010 0.84
62 Epistatic relationship between the cancer susceptibility genes CHEK2 and p27. Cancer Epidemiol Biomarkers Prev 2007 0.84
63 CYP1B1 and predisposition to breast cancer in Poland. Breast Cancer Res Treat 2007 0.83
64 CDH1 gene mutations do not contribute in hereditary diffuse gastric cancer in Poland. Fam Cancer 2010 0.83
65 Common genetic variation at BARD1 is not associated with breast cancer risk in BRCA1 or BRCA2 mutation carriers. Cancer Epidemiol Biomarkers Prev 2011 0.83
66 CHEK2-positive breast cancers in young Polish women. Clin Cancer Res 2006 0.82
67 Direct-to-patient BRCA1 testing: the Twoj Styl experience. Breast Cancer Res Treat 2006 0.82
68 Low prevalence of CDKN2A/ARF mutations among early-onset cancers of breast, pancreas and malignant melanoma in Poland. Eur J Cancer Prev 2008 0.81
69 BARD1 and breast cancer in Poland. Breast Cancer Res Treat 2007 0.81
70 Gene Expression Profiling in Hereditary, BRCA1-linked Breast Cancer: Preliminary Report. Hered Cancer Clin Pract 2006 0.80
71 Integrin beta3 Leu33Pro polymorphism increases BRCA1-associated ovarian cancer risk. J Med Genet 2007 0.79
72 The presence of prostate cancer at biopsy is predicted by a number of genetic variants. Int J Cancer 2013 0.79
73 Duration of tamoxifen use and the risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2014 0.79
74 Low-risk Genes and Multi-organ Cancer Risk in the Polish Population. Hered Cancer Clin Pract 2006 0.78
75 Hereditary breast and ovarian cancer. Hered Cancer Clin Pract 2008 0.77
76 Population screening for cancer family syndromes in the west pomeranian region of poland. Hered Cancer Clin Pract 2006 0.77
77 Breast cancer susceptibility genes. J BUON 2007 0.77
78 The variant allele of the rs188140481 polymorphism confers a moderate increase in the risk of prostate cancer in Polish men. Eur J Cancer Prev 2015 0.77
79 Plasma micronutrients, trace elements, and breast cancer in BRCA1 mutation carriers: an exploratory study. Cancer Causes Control 2012 0.77
80 Ovarian cancer risk in Polish BRCA1 mutation carriers is not associated with the prohibitin 3' untranslated region polymorphism. BMC Cancer 2008 0.76
81 Combined iPLEX and TaqMan assays to screen for 45 common mutations in Lynch syndrome and FAP patients. J Mol Diagn 2009 0.76
82 Does the age of breast cancer diagnosis in first-degree relatives impact on the risk of breast cancer in BRCA1 and BRCA2 mutation carriers? Breast Cancer Res Treat 2015 0.76
83 Corrigendum: Germline RECQL mutations are associated with breast cancer susceptibility. Nat Genet 2016 0.75
84 Coverage of the genetic background of breast cancer in the polish population. Hered Cancer Clin Pract 2006 0.75
85 DNA testing for variants conferring low or moderate increase in the risk of cancer. Hered Cancer Clin Pract 2008 0.75
86 Population Screening of CHEK2 Mutations in Poland. Hered Cancer Clin Pract 2006 0.75
87 Selenium as marker for cancer risk and prevention. Pol Przegl Chir 2012 0.75
88 [Characteristics of selected features of hereditary ovarian cancer in carriers of constitutional BRCA1 gene mutation]. Ginekol Pol 2002 0.75
89 Ovarian cystadenoma as a characteristic feature of families with hereditary ovarian cancers unassociated with BRCA1 and BRCA2 mutations. J Appl Genet 2004 0.75
90 Male to female ratio among offspring of BRCA1 mutation carriers. Breast Cancer Res Treat 2005 0.75
91 Prospective evaluation of alcohol consumption and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2015 0.75
92 The CYP17A1 -34T > C polymorphism and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat 2010 0.75
93 Clinical characteristics of hereditary ovarian cancer (HOC) in Poland. Ginekol Pol 2002 0.75
94 Usefulness of polymorphic markers in exclusion of BRCA1/BRCA2 mutations in families with aggregation of breast/ovarian cancers. J Appl Genet 2003 0.75
95 Colour Doppler ultrasound in preoperative assessment of the neck vessels in patients with tumours of the oral cavity and the neck region. Med Sci Monit 2004 0.75